Radnet Inc Dossier - Source-backed chat

Radnet Inc

RDNTNASDAQ

SectorHealth Care

IndustryDiagnostics & Research

Beta (adjusted)1.26

Intrinsic Value $62.11median of 3 methodsbased on filings through 30 Jun 2026

Market Price $67.70Price as of 1 Oct 2026

Near fair valueIntrinsic value is 8% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $5.3B

Enterprise Value $5.9B

Shares Outstanding 78.5M diluted

Moat Rating None

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

RadNet is successfully executing a dual-track growth strategy: expanding its dominant physical outpatient imaging footprint while rapidly scaling its high-margin DeepHealth AI and digital health software platform. Despite near-term bottom-line pressure from aggressive M&A (such as the $264.1 million acquisition of Gleamer) and labor inflation, RadNet's core business remains highly resilient. The structural shift of diagnostic imaging from high-cost hospital settings to site-neutral outpatient centers, combined with the commercialization of AI-powered workflows like Reporting Pro, positions the company for significant long-term margin expansion and market leadership.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$65.00

Mean target$92.88

High · most bullish analyst$105.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$65.0020%

Integration of Gleamer faces operational delays, and the Digital Health segment continues to post wider-than-expected losses. Elevated labor costs for radiologists and technicians persist, compressing consolidated margins. A slower transition of clinical AI adoption or unexpected Medicare reimbursement cuts under the Physician Fee Schedule limits upside.

Base CaseCentral scenario

$92.8850%

Matches the consensus mean

RadNet successfully integrates Gleamer and achieves its revised 2026 Imaging Center revenue guidance of $2.355B to $2.405B. Digital Health ARR reaches the projected $140 million by year-end, and labor cost pressures are successfully offset by productivity gains from AI-assisted reporting. The stock trades in line with the consensus analyst target.

Bull CaseUpside scenario

$105.0030%

Rapid adoption of DeepHealth AI solutions across both RadNet's network and external clients drives Digital Health ARR well past the $140 million target, leading to early segment profitability. Stronger-than-expected volume growth in advanced imaging modalities (MRI, CT, PET/CT) and favorable payer contracting accelerate operating leverage, pushing the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Unrivaled scale as the largest owner and operator of freestanding outpatient diagnostic imaging centers in the United States, operating 435 centers.
High-growth, high-margin software pivot via the DeepHealth platform, with ARR nearly doubling year-over-year to $96.9 million in Q1 2026.
Strong secular tailwinds from site-of-care migration, as commercial payers and Medicare steer patients toward lower-cost outpatient settings.
Robust balance sheet with $455.3 million in cash and a leverage ratio managed comfortably below 2.0x.

Key Investment Risks

Near-term margin compression from heavy capital expenditures, de novo center builds, and aggressive M&A integration.
Persistent labor shortages and wage inflation for specialized clinical staff, particularly radiologists and technologists.
Reimbursement volatility under the Medicare Physician Fee Schedule and potential regulatory changes.

Thesis Invalidation Triggers

A material decline in Digital Health ARR growth or failure to achieve the $140 million year-end target.
Consolidated leverage ratio exceeding 3.5x due to debt-funded acquisitions without corresponding EBITDA growth.
Severe regulatory or reimbursement cuts that structurally impair outpatient imaging economics.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.